An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination

doi:10.1016/0264-410X(94)90334-4

Vaccine

Volume 12, Issue 11, 1994, Pages 993-999

https://doi.org/10.1016/0264-410X(94)90334-4 Get rights and content

Abstract

The enzyme-linked immunospot assay was used to examine the humoral immune response in 15 healthy volunteers immunized with either split or subunit inactivated trivalent influenza vaccine containing A/Beijing/353/89 (H3N2), A/Taiwan/1/86 (H1N1) and B/Yamagata/16/88. The rapidity of the individual B-cell and serum antibody response was examined in lymphocyte and serum samples collected at various time intervals after vaccination. A rapid serological response was detected with increases in antibody titre detected in the majority of volunteers by 7–8 days postvaccination. Influenza-specific plasma cells were detected as early as 4 days postvaccination, higher numbers of IgA and IgG antibody-secreting cells (ASC) were observed which peaked at 7–8 days postvaccination. The number of ASCs then declined, with low numbers of cells detected at 11 days postvaccination. Influenza-specific IgA ASCs were predominantly of the IgA1 subclass. This rapid immune response may have a bearing on future vaccination policies of unimmunized ‘at risk groups’ in times of high influenza activity.

References (30)

Y. Ghendon
The immune response to influenza vaccines
Acta Virol.
(1990)
B.R. Murphy et al.
The systemic and mucosal immune response of humans to influenza A virus
Curr. Top. Microbiol. Immunol.
(1989)
M.L. Clements et al.
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine
J. Clin. Microbiol.
(1986)
T.A. Brown et al.
Molecular form and subclass distribution of IgA antibodies after immunization with live and inactivated influenza A vaccines
Adv. Exp. Med. Biol.
(1987)
D.C. Powers et al.
Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines
J. Clin. Microbiol.
(1989)
E.J. Remarque et al.
Improvement in immunoglobulin subclass response to influenza vaccine in elderly nursing home residents by the use of high dose vaccines
Vaccine
(1993)
M.A. Zuckerman et al.
Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response
J. Med. Virol.
(1991)
M. Zuckerman et al.
Activity of influenza vaccine against virus strains now circulating
Lancet
(1992)
M.L. Clements et al.
Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine
J. Clin. Microbiol.
(1986)
C. Czerkinsky et al.
A novel two-colour ELISPOT assay

C. Czerkinsky et al.

Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans

Infect. Immun.

(1991)

A. Kantele et al.

Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi

J. Infect. Dis.

(1986)

D.J.M. Lewis et al.

The early cellular and humoral immune response to primary and booster oral immunization with cholera toxin B subunit

Eur. J. Immunol.

(1991)

C. Lue et al.

Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies

J. Immunol.

(1988)

N. Lycke et al.

Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin

Scand. J. Immunol.

(1986)

Cited by (138)

Immune-mediated attenuation of influenza illness after infection: opportunities and challenges
2021, The Lancet Microbe
Sterilising immunity that blocks infection for life, and thus prevents illness after infection, is the ultimate goal for vaccines. Neither influenza infection nor vaccination provide sterilising immunity. Mutations during influenza viral genome replication result in the emergence of viruses that evade immunity and cause reinfections. Waning of immunity also results in reinfections to homologous influenza viruses. However, immunity might limit the severity of disease after infection or vaccination (ie, immunoattenuation). We provide a comprehensive examination of experimental and observational peer reviewed evidence since 1933, when the first influenza virus was isolated, on whether immunity blocks subsequent infection or attenuates illness. Although an abundance of experimental evidence supports immunoattenuation, clinical evidence is rudimentary and conflicting. To the extent that immunoattenuation occurs, understanding the varied pathways to illness, pathogenesis, clinical manifestations, and correlates of attenuation can improve the design and evaluation of influenza vaccines. By elucidating the mechanisms of immunoattenuation and phenotypes of illness, we clarify ambiguities and identify unmet needs that, if addressed with priority, could strategically improve the design of vaccines for the prevention of influenza.
Potential bovine colostrum for human and animal therapy
2021, Current Developments in Biotechnology and Bioengineering: Technologies for Production of Nutraceuticals and Functional Food Products
Colostrum is secreted by the mammal’s glandules during the first days after parturition, it is rich in nutrients and bioactive molecules. This first milk is essential to guarantee the growth and immunity of the newborn, in addition to a balanced nutrition. The high immunoglobulin content in colostrum is responsible for the passive immunity from mother to child. Normally, the production of bovine colostrum (BC) in dairy farms is higher than the calf’s necessity and there is not enough knowledge about the potential of this product; consequently, the spare quantity is discarded. Nowadays researchers have investigated the BC potential as a therapeutic or nutraceutical product, although the spreading of this colostrum potential needs to be more effective among the producers. This chapter reviews the colostrum composition which presents some mechanisms to transfer the passive immunity in different species as well as the potential of colostrum for human and animal therapy.
HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients
2020, Human Immunology
The development of donor specific antibody is associated with graft rejection and increased mortality in solid organ transplant recipients. The majority of de novo donor specific antibodies (dnDSA) are against HLA-DQ antigens, but it has not been investigated if this is caused by more mismatches in the HLA-DQ locus between the recipient and donor. Here we examined the impact of HLA mismatches in eight HLA loci on the development of dnDSA and on rejection in a large cohort of heart transplant recipients. We evaluated HLA mismatches at the antigen level, the eplet level using HLAMatchmaker, and the epitope level using the PIRCHE algorithm. We found that the majority of dnDSA were against HLA-DQ antigens, and the number of dnDSA per mismatch is highest for HLA-DQ compared to other HLA loci. Furthermore, mismatches of HLA-DQ at the epitope level were associated with antibody-mediated rejection. Our results suggest that HLA mismatches at the HLA-DQ locus are more immunogenic than mismatches at other HLA loci to stimulate the development of dnDSA and to cause graft rejection.
Understanding the complex seasonality of seasonal influenza A and B virus transmission: Evidence from six years of surveillance data in Shanghai, China
2019, International Journal of Infectious Diseases
Understanding the complexity of influenza subtype seasonality is critical to promoting a suitable vaccination program. The aim of this study was to identify and compare the seasonality and epidemiological features of seasonal influenza subtypes after the 2009 A/H1N1 pandemic and to lay a foundation for further investigation into the social and environmental factors affecting seasonal influenza virus transmission.
Influenza-like illness (ILI) case surveillance was conducted in two sentinel hospitals in Pudong New Area, Shanghai between 2012 and 2018. Weekly data on ILI cases were analyzed. A time-series seasonal decomposition analysis was used to reveal the seasonality of influenza and epidemiological features among different subtypes.
In total, 10 977 ILI patients were enrolled of whom 2385 (21.7%) had laboratory-confirmed influenza. Compared to influenza A (16.3%), influenza B (5.4%) was less frequently detected among the ILI patients (p < 0.001). Semiannual epidemic peaks were identified in four of the years during the 6-year study period, while only one annual epidemic peak was found in the other two years. An epidemic peak occurred in each winter season, and a secondary peak also occasionally occurred in summer or spring. A/H3N2 predominated in both summer and winter, while A/H1N1, B/Yamagata, and B/Victoria circulated almost exclusively in winter or spring. Two lineages of influenza B seemed to predominate in alternating years.
This study highlights the complexity of seasonal influenza virus activity in a subtropical region of China, presenting both semiannual and annual epidemic peaks in different years. The results of this study may provide further insight into possible improvements in the timing of influenza vaccination in Shanghai, China.
Association between seasonal influenza vaccination with pre- and postnatal outcomes
2019, Vaccine
Citation Excerpt :
This suggests that, even if a pregnant woman initiated prenatal care in the third trimester of pregnancy (about 8% of our pregnant population), vaccination may still offer enhanced immunogenicity and protection against influenza-related adverse fetal and neonatal outcomes. Although our study could not confirm this hypothesis, antibodies to influenza virus are observed in women as early as 2–6 days after vaccination and it is certainly plausible from a biological standpoint [42]. Kharbanda et al. [43] findings were largely similar to ours and the authors concluded that seasonal influenza vaccination during pregnancy was not associated with increased risk of adverse perinatal outcomes.
Influenza vaccination during pregnancy is known to prevent severe influenza illness but its effects on other outcomes and the extent to which its safety is affected by timing of vaccination, maternal race/ethnicity and the type of vaccine is less clear. Therefore, we examined this in a large retrospective cohort.
We analyzed medical and vaccination records from the Kaiser Permanente Southern California (KPSC) records and from the Kaiser Immunization Tracking System (2008–2016). The study included women who were pregnant with singletons during the influenza season. Odds ratios (OR) and their 95% confidence intervals (CI) were used to quantify the associations between immunization status during pregnancy and prenatal and postnatal outcomes after adjusting for confounders.
Of the 247,036 women in these analyses, 53% were vaccinated during their pregnancy. No association between influenza vaccination during pregnancy and adverse prenatal and neonatal outcomes were observed. Influenza vaccination is associated with reduced risk of influenza (OR: 0.49, 95% CI: 0.39–0.62), maternal fever (OR: 0.40, 95% CI: 0.35–0.45), preeclampsia (OR: 0.93, 95% CI: 0.90–0.96), placental abruption (OR: 0.89, 95% CI: 0.82–0.96), stillbirth (OR: 0.88, 95% CI: 0.78–0.99), and NICU admission (OR: 0.89, 95% CI: 0.87–0.92). Both active and inactive vaccines were found to be safe in vaccinated pregnant women regardless of timing of vaccination.
This study found no evidence of adverse maternal and infant outcomes associated with seasonal influenza vaccine during pregnancy. On the contrary, vaccinated women were less likely to have adverse outcomes than unvaccinated women. The lack of increased adverse outcomes associated with influenza vaccination suggests that the benefits of vaccination during pregnancy to the woman and her child far outweigh any risk, if there is one, from the vaccination.
Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine
2018, Vaccine
The 2009 pandemic H1N1 (A(H1N1)pdm09) virus had a highly divergent hemagglutinin (HA) compared to pre-2009 seasonal H1N1 strains. Most peoples were immunologically naïve to the A(H1N1)pdm09, although hospital workers were exposed early in the pandemic before pandemic vaccines became available. Here, we evaluated how pre-existing antibodies influence the induction of cross-functional HA stalk antibodies following A(H1N1)pdm09 vaccination.
Fifty-six healthcare workers vaccinated with AS03 adjuvanted A(H1N1)pdm09 vaccine were chosen by their pre-vaccination priming status (primed HI titers ≥ 40 or unprimed < 40). We analyzed the HA head- and stalk-specific serum IgG subclasses at pre- and 21 days post-vaccination. We also assessed the functionality of the HA stalk-specific antibodies to neutralize virus and mediate antibody dependent cellular cytotoxicity (ADCC).
Primed individuals had higher pre-existing HA head- and stalk-specific IgG1, as well as higher ADCC functionality of stalk antibodies. However, following vaccination with the adjuvanted pandemic vaccine, only the quantity of HA head specific IgG1 antibodies were significantly higher than in unprimed individuals. The priming status did not impact upon the cross-reactive HA stalk specific IgG antibodies or their ability to neutralize virus or induce ADCC post-vaccination. In conclusion, a single dose of AS03 adjuvanted pandemic vaccine elicited similar levels of functional antibodies in naïve and primed individuals. These findings are important for understanding the immunological factors that impact or modulate pandemic vaccine responses in humans.

View all citing articles on Scopus

View full text

PaperAn early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination

Abstract

The immune response to influenza vaccines

Acta Virol.

The systemic and mucosal immune response of humans to influenza A virus

Curr. Top. Microbiol. Immunol.

Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine

J. Clin. Microbiol.

Molecular form and subclass distribution of IgA antibodies after immunization with live and inactivated influenza A vaccines

Adv. Exp. Med. Biol.

Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines

J. Clin. Microbiol.

Improvement in immunoglobulin subclass response to influenza vaccine in elderly nursing home residents by the use of high dose vaccines

Vaccine

Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response

J. Med. Virol.

Activity of influenza vaccine against virus strains now circulating

Lancet

Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine

J. Clin. Microbiol.

A novel two-colour ELISPOT assay

Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans

Infect. Immun.

Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi

J. Infect. Dis.

The early cellular and humoral immune response to primary and booster oral immunization with cholera toxin B subunit

Eur. J. Immunol.

Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies

J. Immunol.

Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin

Scand. J. Immunol.

Paper
An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination